Y-Biologics Statistics

Total Valuation

Y-Biologics has a market cap or net worth of KRW 390.92 billion. The enterprise value is 367.80 billion.

Market Cap	390.92B
Enterprise Value	367.80B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Y-Biologics has 14.95 million shares outstanding. The number of shares has increased by 3.46% in one year.

Current Share Class	14.95M
Shares Outstanding	14.95M
Shares Change (YoY)	+3.46%
Shares Change (QoQ)	+0.61%
Owned by Insiders (%)	29.52%
Owned by Institutions (%)	3.37%
Float	10.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	108.24
PB Ratio	28.38
P/TBV Ratio	29.16
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-42.11
EV / Sales	101.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-64.31

Financial Position

The company has a current ratio of 1.16, with a Debt / Equity ratio of 1.39.

Current Ratio	1.16
Quick Ratio	1.15
Debt / Equity	1.39
Debt / EBITDA	n/a
Debt / FCF	-3.35
Interest Coverage	-22.43

Financial Efficiency

Return on equity (ROE) is -49.24% and return on invested capital (ROIC) is -19.51%.

Return on Equity (ROE)	-49.24%
Return on Assets (ROA)	-14.21%
Return on Invested Capital (ROIC)	-19.51%
Return on Capital Employed (ROCE)	-59.18%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +233.12% in the last 52 weeks. The beta is 3.30, so Y-Biologics's price volatility has been higher than the market average.

Beta (5Y)	3.30
52-Week Price Change	+233.12%
50-Day Moving Average	20,110.40
200-Day Moving Average	12,159.80
Relative Strength Index (RSI)	58.81
Average Volume (20 Days)	669,685

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Y-Biologics had revenue of KRW 3.61 billion and -8.73 billion in losses. Loss per share was -668.31.

Revenue	3.61B
Gross Profit	2.64B
Operating Income	-8.65B
Pretax Income	-8.73B
Net Income	-8.73B
EBITDA	-6.74B
EBIT	-8.65B
Loss Per Share	-668.31

Full Income Statement

Balance Sheet

The company has 42.27 billion in cash and 19.15 billion in debt, giving a net cash position of 23.13 billion or 1,546.95 per share.

Cash & Cash Equivalents	42.27B
Total Debt	19.15B
Net Cash	23.13B
Net Cash Per Share	1,546.95
Equity (Book Value)	13.77B
Book Value Per Share	920.23
Working Capital	5.93B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.26 billion and capital expenditures -463.00 million, giving a free cash flow of -5.72 billion.

Operating Cash Flow	-5.26B
Capital Expenditures	-463.00M
Free Cash Flow	-5.72B
FCF Per Share	-382.60

Full Cash Flow Statement

Margins

Gross margin is 73.14%, with operating and profit margins of -239.38% and -241.85%.

Gross Margin	73.14%
Operating Margin	-239.38%
Pretax Margin	-241.85%
Profit Margin	-241.85%
EBITDA Margin	-186.64%
EBIT Margin	-239.38%
FCF Margin	n/a

Dividends & Yields

Y-Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.46%
Shareholder Yield	-3.46%
Earnings Yield	-2.23%
FCF Yield	-1.46%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Y-Biologics has an Altman Z-Score of -1.58 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.58
Piotroski F-Score	1